Linked Life Data

2844548

Source:http://linkedlifedata.com/resource/pubmed/id/2844548

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2844548rdf:typepubmed:Citationlld:pubmed
pubmed-article:2844548lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0004096lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0521428lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0004048lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0004906lld:lifeskim
pubmed-article:2844548lifeskim:mentionsumls-concept:C0178987lld:lifeskim
pubmed-article:2844548pubmed:issue6lld:pubmed
pubmed-article:2844548pubmed:dateCreated1988-10-31lld:pubmed
pubmed-article:2844548pubmed:abstractTextSixteen patients suffering from bronchial asthma, with or without chronic bronchitis, sufficiently severe to be treated with inhaled corticosteroids, were studied in a single-blind trial (blind observer) of beclomethasone dipropionate (BDP) given in three randomized dosage regimens: 500, 1000 and 2000 micrograms per day, each for 4 weeks. The beta 2-adrenergic agonist response curve showed a dose-dependent increase in FEV1 which was not affected by different doses of BDP. A small but significant reduction in basal cortisol levels was observed after BDP 500 micrograms/day. There was no significant difference between the various doses of BDP in reducing cortisol level and stimulation with tetracosactide remained unchanged. The study showed a gradual, dose-dependent improvement in lung function, statistically significant for morning peak expiratory flow rate at BDP 2000 micrograms/day. Dyspnoea score and beta 2-agonist use decreased, reflecting the anti-asthmatic effects. An increase in total leukocyte count was observed, together with a decrease in the eosinophil count. Oral candidiasis was seen in 2 out of 16 patients. It is concluded that the clinical anti-asthmatic effects of corticosteroid treatment by inhalation are not due to modulation of beta 2-receptor function in the airways.lld:pubmed
pubmed-article:2844548pubmed:languageenglld:pubmed
pubmed-article:2844548pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:citationSubsetIMlld:pubmed
pubmed-article:2844548pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2844548pubmed:statusMEDLINElld:pubmed
pubmed-article:2844548pubmed:issn0031-6970lld:pubmed
pubmed-article:2844548pubmed:authorpubmed-author:LammersJ WJWlld:pubmed
pubmed-article:2844548pubmed:authorpubmed-author:FolgeringH...lld:pubmed
pubmed-article:2844548pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:2844548pubmed:authorpubmed-author:MolemaJJlld:pubmed
pubmed-article:2844548pubmed:issnTypePrintlld:pubmed
pubmed-article:2844548pubmed:volume34lld:pubmed
pubmed-article:2844548pubmed:ownerNLMlld:pubmed
pubmed-article:2844548pubmed:authorsCompleteYlld:pubmed
pubmed-article:2844548pubmed:pagination577-83lld:pubmed
pubmed-article:2844548pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:meshHeadingpubmed-meshheading:2844548-...lld:pubmed
pubmed-article:2844548pubmed:year1988lld:pubmed
pubmed-article:2844548pubmed:articleTitleEffects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma.lld:pubmed
pubmed-article:2844548pubmed:affiliationDepartment of Pulmonary Diseases, Medical Centre Dekkerswald, University of Nymegen, Groesbeek, The Netherlands.lld:pubmed
pubmed-article:2844548pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2844548pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2844548pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2844548lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2844548lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2844548lld:pubmed